Iguratimod as Treatment for Refractory Lupus Nephritis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study is to evaluate the efficacy and safety of a novel chemical synthetic agent iguratimod as treatment of refractory lupus nephritis. All subjects should have at least one failed immunosuppressive treatment and suffer active nephritis at the screening stage. The study period is 52 week. All the subject will receive therapy of iguratimod combined with steroids.
Epistemonikos ID: d22f84dc28306ff0ab4b9b51edf47d8c7fd23228
First added on: May 20, 2024